May 2022 in “Experimental dermatology” Trichothiodystrophy hair is structurally abnormal with protein and organization issues.
TrichoSolTM is safe for hair loss treatments with specific ingredient stability for up to 180 days.
March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
January 2015 in “International Journal of Nanomedicine” Anionic squarticles can effectively counteract amitriptyline overdose, improving survival rates.
400 citations
,
October 1995 in “Journal of clinical oncology” Docetaxel is effective against various cancers but mainly causes neutropenia.
31 citations
,
August 2001 in “PubMed” TrichoScan accurately measures hair growth and showed improved hair counts and thickness after finasteride treatment.
22 citations
,
May 2011 in “European Journal of Cancer” The drug combination was safe and showed promise in treating advanced tumors.
February 2026 in “Indian Journal of Dermatology” Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.
75 citations
,
September 1971 in “British Journal of Dermatology” Both steroids effectively promote hair growth for at least 9 months.
September 2022 in “Journal of The American Academy of Dermatology” Combining dutasteride mesotherapy with oral minoxidil is more effective for hair loss than using oral minoxidil alone.
Acitretin improved monilethrix symptoms temporarily, but they returned after stopping treatment.
12 citations
,
June 2011 in “Journal of Dermatological Case Reports” Shaving, erythromycin cream, and clotrimazole powder effectively treated the bad odor and rough hair.
2 citations
,
May 2024 in “International Journal of Dermatology” April 2013 in “The FASEB Journal” Dutasteride showed some prevention of prostate issues but also had limitations, especially with high-grade tumors.
2 citations
,
June 2024 in “International Journal of Drug Delivery Technology” Advanced delivery systems can make dithranol more effective and less irritating for treating psoriasis.
December 2023 in “Magna Scientia Advanced Research and Reviews” The document suggests using trazodone and clomiphene to treat sexual dysfunction caused by post-finasteride syndrome.
June 2023 in “Clinical Cosmetic and Investigational Dermatology” Pentoxifylline effectively improves pretibial pruritic papular dermatitis.
July 2023 in “Zenodo (CERN European Organization for Nuclear Research)” Trazodone and chlorpromazine may help treat sexual dysfunction caused by finasteride and SSRIs.
July 2014 in “Journal of the Portuguese Society of Dermatology and Venereology” Trichoscopy is useful for diagnosing and monitoring hair and scalp conditions.
September 2025 in “JAAD International” Thrice-weekly dutasteride improved hair density and thickness more than twice-weekly, but not hair count compared to daily finasteride.
1 citations
,
January 2021 in “Dermatologic Therapy” Trichobiolight effectively treats hair loss with 82.5% success.
January 2020 in “Journal of Men s Health” The combination treatment reduced prostate size and improved testosterone deficiency symptoms but was less effective for sexual function.
March 2026 in “Preprints.org” Plerixafor may help treat pigmentation disorders by promoting skin repigmentation.
February 2026 in “Oncology Reviews” Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
February 2006 in “Journal of The American Academy of Dermatology” Terbinafine is more effective than itraconazole for toenail fungus, especially in older patients, and debridement improves its effectiveness.
November 2024 in “Nanomaterials” The nanocrystalline suspension effectively delivers dutasteride over time with minimal inflammation.
28 citations
,
October 2010 in “Targeted Oncology” Trastuzumab may cause tufted hair folliculitis as a side effect.
9 citations
,
October 1947 in “The Lancet” 1 citations
,
November 1947 in “The Lancet” February 2016 in “PubMed” Properly administered testosterone therapy is safe and effective but often not covered by insurance.